Option chain shows key data for SanBio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for SanBio.

SanBio (OTC:SNBIF) Stock, Option Chain

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co Ltd

<ul>
<li>EPIC Advanced Packaging marks an expansion of Applied's global innovation platform</li>
<li>Company convenes top semiconductor R&amp;D leaders to advance high-performance, low-power AI chip packaging technologies</li>
</ul>

News

AMAT

Applied Materials Expands Global Innovation Platform With Advanced Packaging Collaboration For AI Era

Proceeds to be used primarily to acquire bitcoin and repurchase existing convertible notes due 2026

MARA

Reported Earlier, MARA Holdings Prices $850M Oversubscribed And Upsized Zero-Coupon Convertible Notes Offering Due 2030

Hyperlux advanced imaging capabilities capture most accurate visual data to ensure error-free interpretation of driving environments and enhance car safety&nbsp;
NEWS HIGHLIGHTS
<ul>
<li>onsemi will be the primary supplier of image sensors for Subaru's next-generation EyeSight stereo-camera front sensing system</li>
<li>Hyperlux image sensors feature whole pixel design and High Dynamic Range to significantly improve image clarity and accuracy</li>
<li>Equipped with functional safety features, Hyperlux sensors ensure greater level of safety and reliability of the system</li>
<li>Selection follows longstanding collaboration between companies to improve vehicle safety by tailoring sensors to multiple generations of Subaru's stereo-camera front sensing system</li>
</ul>

Reported Earlier, Subaru Selects onsemi Hyperlux Sensors To Enhance AI-Integrated EyeSight Driver Assistance System

Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –
– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –
– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –
– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –

Reported Earlier, Vir Biotechnology Announces Phase 2 Data And Phase 3 Launch For Chronic Hepatitis Delta Treatment

SYRE

Reported Earlier, Spyre Therapeutics Prices $200M Public Offering Of 7.275M Common Shares At $27.50/Share

The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $6.9 million before deducting the placement agent's fees and other offering expenses payable by the Company. The offering is expected to close on or about November 20, 2024, subject to the satisfaction of customary closing conditions.

HCWB

Reported Earlier, HCW Biologics Announces $6.9M Direct Offering And Private Placement Priced Above Market

Select intends to use the net proceeds of the Offering, together with the proceeds from the proposed new incremental term loan and cash on hand, to repay in full the term loans currently outstanding under Select's existing senior secured credit agreement, to redeem all of Select's outstanding 6.250% senior notes due 2026 and to pay fees and expenses related to the foregoing.&nbsp;

Reported Earlier, Select Medical Announces Pricing of $550M 6.250% Senior Notes Due 2032

The fundamentals of our business are strong. Our AirSCWO technology is performing well across biosolid/sludge and liquid waste streams. Our DaaS business is taking shape representing near-term recurring revenue, with our first operating site being actively negotiated to destroy non-hazardous waste, and our conversations are advancing with TSDF operators for onsite non-hazardous and hazardous waste destruction. Our approach to opening markets is bearing fruit with opportunities across AFFF, GAC, IX, and other organic waste streams. Our current backlog/pipeline exceeds $1.8B and we believe this will grow further.

SCWO

Reported Earlier, 374Water Highlights Commercial Milestones, $1.8B Pipeline, And Growing Opportunities In Waste Management

Telix's development program will initially focus on the treatment of bladder cancer, rounding out its urology franchise, which includes late-stage therapeutic programs for kidney and prostate cancers.
FAP is a pan-cancer marker expressed in the tumor microenvironment of epithelial cancers and on the surface of some specific cancer types, including sarcomas and mesotheliomas.

Reported Earlier, Telix Expands Theranostic Pipeline With FAP-Targeting Radiopharmaceuticals For Pan-Cancer Treatment

The Company stated that while its financial position remains sound, the Board of Directors determined that the reduction in the dividend was prudent given the Company's recent operating performance. As previously disclosed, the Company has been implementing multiple initiatives to improve performance that have led to year-over-year performance improvement. These include price adjustments with our customers and cost reduction projects, including the previously disclosed consolidation of the&nbsp;Albia, Iowa operation into the Tyrone, Pennsylvania operation.

Reported Earlier, Chicago Rivet & Machine Reduces Quarterly Dividend To $0.03 Per Share From $0.10 Per Share, Payable December 20, 2024

Earnings

ZENV

Reported Earlier, Zenvia Q3 Sales R$284.400M Beat R$249.810M Estimate; Net Income R$52.62M Up From Net loss R$11.94M

ZEPP

Reported Earlier, Zepp Health Q3 EPS $(0.78) Down From $0.12 YoY, Sales $42.50M Down From $82.53M YoY

<ul>
<li>IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL</li>
<li>IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a range of B-NHL cell lines, in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patients</li>
<li>In vivo studies further validated that IPH6501 augments the ability of peripheral NK cells to migrate and infiltrate tumors</li>
<li>Results support clinical development of IPH6501 in R/R B-NHL</li>
</ul>

IPHA

Innate Pharma Publishes Preclinical Data Demonstrating The Potential Of IPH6501 In Science Immunology

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) to report quarterly earnings at 53 cents per share on revenue of $167.72 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Walmart shares rose 1.6% to $85.44 in after-hours trading.</li>
<li>AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) reported better-than-expected earnings for its fourth quarter. The company's quarterly earnings came in at $1.27 per share which beat the analyst consensus estimate of $1.24 per share. The company reported quarterly sales of $4.11 billion versus the analyst consensus estimate of $4.14 billion. Aecom shares fell 1.2% to $107.80 in the after-hours trading session.</li>
<li>Analysts expect Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) to post quarterly earnings at $2.82 per share on revenue of $19.94 billion. The company will release earnings before the markets open. Lowe&#8217;s shares gained 0.1% to $272.10 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) reported better-than-expected results for its fourth quarter on Monday. For the first quarter of fiscal 2025, Symbotic expects revenue of $495 million to $515 million, versus the $495.73 million estimate, and adjusted EBITDA of $27 million to $31 million. Symbotic shares jumped 26.3% to $38.60 in the after-hours trading session.</li>
<li>Analysts expect Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) to report quarterly earnings at $1.25 per share on revenue of $8.27 billion before the opening bell. Medtronic shares gained 0.2% to $87.74 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>
Image via Wikimedia Commons

Pre-Market Outlook

Markets

Trading Ideas

Walmart, Lowe's And 3 Stocks To Watch Heading Into Tuesday

<ul>
<li>Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activity</li>
<li>A greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care alone</li>
<li>Systemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ systems, primarily in women, for whom there is a significant need for additional treatment options</li>
</ul>

BIIB

UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction

The Airline Offers New Low-Cost Travel Options to Popular Destinations in 51 Cities

ALGT

Reported Earlier, Allegiant Expands Nationwide With 44 Routes And $39 Fares, Adding Gulf Shores, Columbia, And Colorado Springs

Creates a leading North American lithium producer and developer
<ul>
<li>Piedmont and Sayona to combine in all-stock merger with ownership split of approximately 50% / 50% on a fully diluted basis immediately post-merger and prior to the conditional equity raising</li>
<li>Creating a leading North American hard rock lithium producer with geographically advantaged spodumene resources of global scale</li>
<li>Simplified corporate structure aligns North American Lithium ("NAL") offtake economics, and removes contractual complexities</li>
<li>Unified ownership of NAL unlocks the potential for a significant brownfield expansion</li>
<li>Combined scale provides strategic flexibility to combine and optimize downstream strategies</li>
<li>Material corporate, logistics, marketing, and procurement synergies</li>
<li>Significantly strengthened balance sheet with two stage equity financing, with post-merger raise led by cornerstone subscription from Resource Capital Fund VIII L.P. ("RCF VIII"), associated with Resource Capital Funds ("RCF"), a critical minerals and mining-focused global investment firm</li>
<li>MergeCo will endeavor to complete an additional equity raise for eligible retail shareholders post-closing</li>
</ul>

Reported Earlier, Piedmont And Sayona Merge To Form North America's Largest Hard Rock Lithium Producer

2025 Outlook
The Company's practice is to provide annual guidance, excluding the impact of future acquisitions, dispositions and transaction-related costs.
The Company is providing the following outlook for the fiscal year ending September 30, 2025, which remains unchanged from the previous guidance included in the Company's earnings release issued on August 8, 2024:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(in thousands, except share and per share amounts)</td>
<td colspan="5" rowspan="1">Outlook Range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="5" rowspan="1">Fiscal year ending September 30, 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">243,000</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">263,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (non-GAAP)</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">63,000</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">71,500</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and internally developed software amortization</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">12,000</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">14,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash interest expense</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1,000</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pro forma adjusted diluted earnings per share(1)(non-GAAP)</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1.05</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1.25</td>
</tr>
</tbody>
</table>
</figure>

Guidance

IIIV

i3 Verticals Reaffirms FY25 Guidance: Sees Pro Forma EPS From Continuing Operations Of $1.05-$1.25, Revenue From Continuing Operations Of $243M-$263M

Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and&nbsp;Elon Musk&#8217;s SpaceX&nbsp;may encounter obstacles in their attempts&nbsp;to block the National Labor Relations&nbsp;Board or NLRB cases.
What Happened: On Monday, a panel of U.S. judges suggested that both companies might have prematurely brought their challenges to the NLRB&#8217;s structure to&nbsp;the 5th U.S. Circuit Court&nbsp;of Appeals, reported Reuters.
The panel&nbsp;questioned whether Amazon and SpaceX&nbsp;should have allowed more time for Texas judges&nbsp;to rule before filing appeals.
The legal challenges, if successful, could potentially weaken the NLRB&#8217;s powers. Even if they fail, some have already managed to indefinitely delay NLRB cases.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42026410/nvidia-apple-suppliers-prepare-for-policy-shifts-japans-ai-leap-and-amds-workforce-cut-this-week-in-ai?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nvidia, Apple Suppliers Prepare For Policy Shifts, Japan&#8217;s AI Leap, And AMD&#8217;s Workforce Cut: This Week In AI</a>
Amazon and SpaceX are separately trying to block NLRB&nbsp;cases accusing them of illegal&nbsp;labor practices.
Amazon is fighting a case related to its first-ever union at a warehouse in New York City. SpaceX is facing accusations of firing engineers who criticized Musk — a claim the company denies.
Amazon and SpaceX argue that&nbsp;federal judges in Texas &#8220;effectively&nbsp;denied&#8221; their petitions to block&nbsp;NLRB cases&nbsp;by not ruling on them&nbsp;promptly. However, the judges in both cases&nbsp;ruled that the lawsuits did&nbsp;not belong in Texas.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: This development follows a series of legal disputes involving the NLRB and major corporations.
Other companies, <a href="https://www.benzinga.com/markets/equities/24/08/40570061/chipotle-accused-by-labor-watchdog-of-unlawfully-withholding-pay-raises-from-unionized-workers">including</a>&nbsp;Chipotle Mexican Grill&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>),&nbsp;Stellantis&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>), and&nbsp;Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), have <a href="https://www.benzinga.com/markets/equities/24/10/41136199/apple-accused-of-violating-federal-law-over-alleged-illegal-employee-agreements-nlrb-hearing-set">also faced NLRB</a> complaints for <a href="https://www.benzinga.com/news/24/09/40894503/uaw-files-nlrb-complaint-against-stellantis-over-alleged-contract-violations-says-it-intends-to-make">alleged labor violations</a>.
Earlier this year,&nbsp;Amazon argued that the <a href="https://www.benzinga.com/news/24/02/37191759/jeff-bezos-amazon-joins-spacex-and-trader-joes-in-slamming-nlrb-amid-labor-union-dispute">NLRB was unconstitutional</a>&nbsp;in response to a case accusing the company of unlawfully retaliating against workers who voted to unionize.
In October, the&nbsp;<a href="https://www.benzinga.com/government/24/10/41171072/amazon-accused-of-union-busting-after-drivers-unionize-nlrb-files-complaint">NLRB charged Amazon</a>&nbsp;for failing to acknowledge and bargain with the Teamsters Union.
In SpaceX&#8217;s case, NLRB alleged that the company violated federal labor laws by firing employees who, in June 2022, circulated a letter criticizing Musk's controversial tweets and calling him a &#8220;<a href="https://www.benzinga.com/news/24/01/36484393/spacex-wrongfully-fired-employees-who-called-elon-musk-distraction-and-embarrassment-us-labor-agency">distraction and embarrassment</a>.&#8221;
Price Action: Amazon shares closed Monday's session down 0.45% at $201.70. In after-hours trading, the stock gained slightly, reaching $201.89 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo Courtesy: T. Schneider On Shutterstock.com
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41872302/taylor-swift-fans-abandon-elon-musks-x-for-bluesky-how-trumps-election-victory-triggered-swifties-uprising?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Taylor Swift Fans Abandon Elon Musk&#8217;s X For Bluesky, Says Report: How Trump&#8217;s Election Victory Triggered Swifties Uprising</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Politics

Tech

Media

AAPL

AMZN

STLA

Amazon And SpaceX's Efforts To Block NLRB Cases In Jeopardy As Appeals Court Raises Key Legal Concerns

i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $0.17 by 11.76 percent. This is a 6.25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $60.864 million which missed the analyst consensus estimate of $61.250 million by 0.63 percent. This is a 36.87 percent decrease over sales of $96.407 million the same period last year.

Earnings Misses

i3 Verticals Q4 2024 Adj. EPS $0.15 Misses $0.17 Estimate, Sales $60.864M Miss $61.250M Estimate

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. announces conditional and time-limited approval for its ‘AKUUGO Suspension for Intracr...

SanBio's AKUUGO Suspension Nears Market Launch

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has updated stakeholders on the approval process of their AKUUGO suspension for intrac...

SanBio Co. Clarifies AKUUGO Suspension Approval

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has announced new research findings that detail the mechanisms of action for its key p...

SanBio Reveals Breakthrough in Brain Regeneration Research

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has announced that the US Patent and Trademark Office has granted a Notice of Allowanc...

SanBio Co. Granted US Patent for Stroke Cell Therapy

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has announced the conditional and time-limited marketing approval in Japan for ‘AKUUGO...

SanBio's Revolutionary TBI Treatment Approved

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. announced that its development product SB623, aimed at treating chronic motor paralysi...

SanBio's SB623 Shows Long-Term Motor Function Improvements

SanBio Co (JP:4592) has released an update. SanBio Co., a company listed on the TSE Growth market, has released its financial results for the secon...

SanBio's Q2 Financials and Regenerative Medicine Push

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. announced that the Fourth Pharmaceutical Affairs Council meeting of FY2024 included a ...

SanBio Reports on Regenerative Medicine Progress

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has been granted a new patent in the US for its cell therapy product SB623, aimed at t...

SanBio Secures US Patent for Stroke Therapy

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. experienced a minor setback in the first production run of AKUUGO, a stem cell therapy...

Comments

SanBio

SanBio (SNBIF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga